Nuzyra
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.nuzyra.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Nuzyra
Paratek Pharmaceuticals, Inc. specializes in innovative antibiotic treatments, notably NUZYRA® (omadacycline), which addresses Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults. The company targets healthcare professionals in the United States through their comprehensive resources and support programs for prescribing and patient access. NUZYRA is positioned as a next-generation tetracycline that offers efficacy for patients with specific bacterial infections. The company emphasizes the importance of appropriate antibiotic use to combat drug resistance.Explore more
Popular SearchesNuzyraParatek Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nuzyra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nuzyra
Click to see if Nuzyra had a recent Job posting/layoffs
Check if Nuzyra has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nuzyra launches new products
Nuzyra, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Nuzyra is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Nuzyra has new funding data
Earning: See what the market has to say on Nuzyra recently announced quarterly report
Recommended Actions
Find VP level buyers at Nuzyra
Find more new buyers
Compare Similar Companies to Nuzyra
Compare insights from companies similar to Nuzyra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nuzyra
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Nuzyra is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nuzyra is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nuzyra.
Nuzyra Tech Stack
A closer look at the technologies used by Nuzyra
Nuzyra News & Media
Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. announced today the publication of data from an investigator-initiated study evaluating the activity of NUZYRA® (omadacycline) in a dynamic hollow fiber model of Mycobacterium avium complex (MAC) pulmonary infection.Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior QuarterParatek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
-- Potential $1 Billion Addressable Market Opportunity in the United States -- Potential $1 Billion Addressable Market Opportunity in the United StatesParatek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nuzyra
Sign Up For FreeTo access detailed company insights
Paratek Pharmaceuticals, Inc. specializes in innovative antibiotic treatments, notably NUZYRA® (omadacycline), which addresses Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults. The company targets healthcare professionals in the United States through their comprehensive resource... Read More
